CD274 and hepatocellular carcinoma: This demonstrates an effective advantage of PD-L1 targeting, better to an extent in a combination therapy with epigenetic targeting using DNA methylation inhibitor, for at least in the progenitor HCC subtype among heterogeneous HCC cells.